Stockscreener 앱 받기
4.25
2.07%
-0.09
전일 마감가:
$4.34
열려 있는:
$4.37
하루 거래량:
134.19K
Relative Volume:
0.87
시가총액:
$99.70M
수익:
$7.94M
순이익/손실:
$-21.13M
주가수익비율:
-3.9286
EPS:
-1.0818
순현금흐름:
$-16.17M
1주 성능:
-14.14%
1개월 성능:
-4.71%
6개월 성능:
-5.13%
1년 성능:
-32.54%
1일 변동 폭
$4.16
$4.39
1주일 범위
$4.14
$5.05
52주 변동 폭
$3.7101
$7.55
Coya Therapeutics Inc Stock (COYA) Company Profile
명칭
Coya Therapeutics Inc
전화
650.739.3939
주소
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.25 | 99.70M | 7.94M | -21.13M | -16.17M | -1.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-05 | 개시 | Roth Capital | Buy |
| 2025-07-09 | 개시 | Lake Street | Buy |
| 2024-12-04 | 개시 | D. Boral Capital | Buy |
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
Coya Therapeutics, Inc. (COYA) stock price, news, quote and history - Yahoo Finance Singapore
Coya Gains on Test News - baystreet.ca
An ALS trial hits its enrollment target at Coya Therapeutics (COYA), with results expected in early Q2 2027. - Stock Titan
Coya Therapeutics Hits Enrollment Milestone with 100 Patients in Phase 2/3 ALSTARS ALS Trial - Kalkine Media
Coya Therapeutics, Inc. Common Stock (NASDAQ: COYA) Stock Price, News & Analysis - kalkine.ca
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation - BioSpace
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation - Business Wire
$32 Million Exosome Therapy Market Assessment 2026: Set to Experience Massive Growth, Reaching $1.4 Billion by 2040 - GlobeNewswire Inc.
COYA: Treg-based combination therapies show promise in ALS and FTD, with key data expected in 2027 - TradingView
Coya Therapeutics Advances Phase 2 ALSTARS ALS Trial Toward 2026 Enrollment Finish - Streetwise Reports
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Is This Biopharmaceutical Co. Developing ALS Drug a Buy? - Streetwise Reports
H.C. Wainwright reiterates Coya Therapeutics stock rating at buy By Investing.com - Investing.com UK
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT) - The Globe and Mail
Coya Therapeutics (COYA) Holds Ground at $4.67 as Consolidation ContinuesOBV Divergence - vinanet.vn
Experimental ALS treatment being tested in Philadelphia: "There's potential here for a home run" - CBS News
Coya Therapeutics (COYA) Edges Up 0.85% to $4.73, Holding Support Amid ConsolidationGEX Level - vinanet.vn
COYA Q1 2026 Earnings: Narrower-Than-Expected Loss Offers a Favorable SurpriseNext Quarter Guidance - vinanet.vn
COYA Pulls Back to $4.69: Coya Therapeutics Approaches Critical Support LevelHigh Dividend Factor - vinanet.vn
COYA Pulls Back to $4.69: Coya Therapeutics Approaches Critical Support LevelLow Volume Node - dars.gov.et
Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom - Streetwise Reports
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Form 8K Coya Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Coya Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases - Bitget
Form 8K Coya Therapeutics Inc For: 11 August By Investing.com - Investing.com Canada
Coya Therapeutics reports Q2 2026 net loss $6.64M, cash $43.2M; ALSTARS Phase 2 enrollment on track - TradingView
Coya Therapeutics Q2 net loss widens as R&D costs rise - TradingView
Coya Therapeutics Reports Q2 Net Loss of $6.6 Million - Quiver Quantitative
Coya Therapeutics (NASDAQ: COYA) details Q2 2026 results, ALS Fast Track and cash runway - Stock Titan
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics (NASDAQ:COYA): What Could Today’s Update Reveal About Clinical Execution And Funding Priorities? - Kalkine Media
COYA Q1 2026 Earnings: 24.1% EPS Beat Narrows Loss, Shares Rise 1.72%Margin Expansion Trends - vinanet.vn
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - BioSpace
IMDX Stock Price and Chart — NASDAQ:IMDX - tradingview.com
Coya Therapeutics (NASDAQ: COYA) names Mark Pavao to its Audit Committee - Stock Titan
Coya Therapeutics, Inc. Appoints Mark H. Pavao to Its Audit Committee of Board, Effective August 7, 2026 - marketscreener.com
Coya Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Coya Therapeutics (COYA) Rallies 3.71% as Shares Press Toward Key $5 LevelSweep Order Flow - dars.gov.et
Treg Therapy Market - Future Market Insights
Coya Therapeutics (COYA) Expected to Release Earnings on Tuesday - MarketBeat
Avoiding Lag: Real-Time Signals in (COYA) Movement - Stock Traders Daily
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Drives 2.7% Stock UptickMargin Improvement Report - vinanet.vn
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline in Pre-Revenue Stage - vinanet.vn
COYA Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 5.4%Net Profit Margin - vinanet.vn
Coya Therapeutics (COYA) Holds Steady at $4.0 Amid Key Support and Resistance BattleNegative Gamma - vinanet.vn
Coya Therapeutics Inc (COYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):